While recent studies in mice have confirmed that CSF1R inhibition decreased tumor growth in PDGFB-driven GBM, they also reported that it failed to show beneficial effects in mice bearing mesenchymal RAS-driven GBMs or other proneural and mesenchymal GBMs (129). The gene discussed is CSF1R; the disease is neoplasm.